Galectin-3、CD44v6在滤泡上皮起源甲状腺肿瘤中的表达及意义
|
摘要
目的探讨Galectin-3、CD44v6在滤泡上皮起源的甲状腺肿瘤中表达的异同性,分析表达强度与表达分布特性,从而试解释生物学特性、相互间的关系为本课题研究目的。方法应用Envision二步免疫组织化学方法检测Galectin-3、CD44v6在30例甲状腺乳头状癌、11例甲状腺滤泡癌、3例甲状腺未分化癌、9例甲状腺滤泡腺瘤及5例桥本氏甲状腺炎中的表达。甲状腺肿瘤旁组织作为对照。结果1.Galectin-3、在乳头状癌、滤泡癌、未分化癌、滤泡腺瘤及桥本氏甲状腺炎组中阳性表达率分别为100.00%(30/30)、100.00%(11/11)、100.00%(3/3)、33.33%(3/9)、100.00%(5/5),对照组与各组间阳性表达差异有统计学意义(P<0.01)。2.CD44V6在乳头状癌、滤泡癌、未分化癌、腺瘤、桥本氏甲状腺炎组中阳性表达率分别为90.00%(27/30)、81.81%(9/11)、66.67%(2/3)、66.67%(6/9)、60.00%(3/5),对照组与各组间阳性表达差异有统计学意义(P<0.001)。3.Galectin-3与CD44V6在甲状腺乳头状癌表达的正相关性为27/30(90%),两者之间呈相关性(r=0.69,P<0.05)。4.Galectin-3与CD44V6在甲状腺滤泡癌表达的正相关性为9/11(81.81%),两者之间呈相关性(r=0.63,P<0.05).结论Galectin-3、CD44V6在滤泡上皮起源甲状腺肿瘤组织中的表达特性揭示其肿瘤之间存在的型转化、恶性转化之相关性;联合检测Galectin-3、CD44V6可能是滤泡上皮起源甲状腺肿瘤病理鉴别诊断及临床预后的重要生物学标记物指。
Objective Study the expression of Galectin-3 and CD44v6 which similarities and differences, distributed feature and heightis in follicular epithelium neapelsm of the thyroid. Methods Envision immunohistological method were used to examine the expression of Galectin-3, CD44v6 and compared among the tumor specimens of thyroid papillary carcinoma(n=30), follicular thyroid carcinoma (n=11), undifferentiated carcinoma (n=3), follicular adenoma (n=9), hashimotos’s thyroiditis(n=5). Results 1) The positive rates of Galectin-3 were 100.00%(30/30)?100.00%(11/11)?66.67%(2/3)、33.33%(3/9)100. 00%(5/5) for thyroid papillary carcinoma, follicular thyroid carcinoma, follicular adenoma, undifferentiated carcinoma and hashimotos’s thyroiditis, respectinvely. Compared with contrast group, the expression of Galectin-3 for thyroid papillary carcinoma and follicular thyroid carcinoma were significantly enhanced (P<0.01); 2) The positive rates of CD44v6 were 90.00%(27/30)?81.81%(9/11)?66.67%(6/9)、66.67%(2/3)、60.00%(3/5) for thyroid papillary carcinoma, follicular thyroid carcinoma, follicular adenoma, undifferentiated carcinoma and hashimotos’s thyroiditis, respectinvely. Compared with contrast group, the expression of CD44v6 for thyroid papillary carcinoma and follicular thyroid carcinoma were significantly enhanced (P<0.05); 3)The positive rates of Galectin-3 and CD44v6 were 27/30(90.00%)for Papillary thyroid carcinoma and be interrelated(r=0.69,P<0.05). 4) The positive rates of Galectin-3 and CD44v6 were 9/11(81.81%)for Follicular thyroid carcinoma and be interrelated(r=0.63,P<0.05). Conclusion The characteristic expression of Galectin-3 and CD44v6 will be revealed that have had typeis and malignant change in follicular epithelium neapelsm of the thyroid. Co-expression of Galectin-3 and CD44v6 will be important for diganosis and survivor in follicular epithelium neapelsm of the thyroid.
Objective Study the expression of Galectin-3 and CD44v6 which similarities and differences, distributed feature and heightis in follicular epithelium neapelsm of the thyroid. Methods Envision immunohistological method were used to examine the expression of Galectin-3, CD44v6 and compared among the tumor specimens of thyroid papillary carcinoma(n=30), follicular thyroid carcinoma (n=11), undifferentiated carcinoma (n=3), follicular adenoma (n=9), hashimotos’s thyroiditis(n=5). Results 1) The positive rates of Galectin-3 were 100.00%(30/30)?100.00%(11/11)?66.67%(2/3)、33.33%(3/9)100. 00%(5/5) for thyroid papillary carcinoma, follicular thyroid carcinoma, follicular adenoma, undifferentiated carcinoma and hashimotos’s thyroiditis, respectinvely. Compared with contrast group, the expression of Galectin-3 for thyroid papillary carcinoma and follicular thyroid carcinoma were significantly enhanced (P<0.01); 2) The positive rates of CD44v6 were 90.00%(27/30)?81.81%(9/11)?66.67%(6/9)、66.67%(2/3)、60.00%(3/5) for thyroid papillary carcinoma, follicular thyroid carcinoma, follicular adenoma, undifferentiated carcinoma and hashimotos’s thyroiditis, respectinvely. Compared with contrast group, the expression of CD44v6 for thyroid papillary carcinoma and follicular thyroid carcinoma were significantly enhanced (P<0.05); 3)The positive rates of Galectin-3 and CD44v6 were 27/30(90.00%)for Papillary thyroid carcinoma and be interrelated(r=0.69,P<0.05). 4) The positive rates of Galectin-3 and CD44v6 were 9/11(81.81%)for Follicular thyroid carcinoma and be interrelated(r=0.63,P<0.05). Conclusion The characteristic expression of Galectin-3 and CD44v6 will be revealed that have had typeis and malignant change in follicular epithelium neapelsm of the thyroid. Co-expression of Galectin-3 and CD44v6 will be important for diganosis and survivor in follicular epithelium neapelsm of the thyroid.
引文
[1]尼加提.热合木,居来提.吐尔荪,阿布都卡的.依马木,滤泡上皮起源甲状腺腺癌特异性生物标记物研究进展,新疆医科大学学报2007Apr., 30(4), 420-423
[2]田丰秋,吕丽,冯晓海,王乃玉,张文波,王莉芬,甲状腺乳头状癌的诊断及转移相关的免疫组化研究,中华肿瘤防治杂志2007年7月第14卷第13期, 789·
[3]桌明英,扬军,甲状腺乳头状癌中CD44v6和P53的表达及其意义,实用肿瘤学杂志2007年第21卷第3期总第89期, 253
[4]肖红,段绍斌,张建勇,范健,甲状腺组织中galectin-3、CK19的表达及应用价值,新疆医科大学学报, 2006 Nov.,29(11),9501
[5]王化修,伍石华,蒙松年,肖小芹,扬华,存活素和CD44v6在甲状腺癌组织中的表达及意义,使用癌症杂志2006年11月第21卷第6期, 885
[6]徐莹(综述),甲状腺肿瘤Galectin-3表达及其意义, Fudan Univ J med Sci 2002 May,29(3),230-232
[7]王丽华,赵咏桔, Galectin-3、CD44v6在甲状腺结节型中的的表达及其意义,中华肿瘤杂志2005年第27卷第9期, 547
[8]徐莹(综述),甲状腺肿瘤Galectin-3表达及其意义, Fudan Univ J med Sci 2002 May,29(3),230-232
[9] Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Mod Pathol. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. 2006 Dec;19(12):1631-7. Epub 2006 Sep 22
[10]王丽华,赵咏桔, Galectin-3、CD44v6在甲状腺结节型中的的表达及其意义,中华肿瘤杂志2005年第27卷第9期, 547
[11]陈宁,梁青春,甲状腺乳头状癌淋巴管密度与CD44v6表达及其意义,使用预防医学2007年6月第14卷第3期, 188
[12] BrianHung-HinLang, Chung-YauLo, Wai-FanChan, King-YinLam 2andKoon- YatWanStaging systems for follicularthyroidcarcinoma: applicationto171 consecutivepatientstreatedinatertiaryreferralcentreEndocrine-RelatedCancer (2007) 14 29(R)C4,31-32
[13] DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006 Dec 15;94(8):662-9
[14]王佾, Galectin23在甲状腺良恶性病变中的表达,中国普通外科杂志Vol.15No.1,第16卷第1期2007年1月,51-54
[15] Beesley MF, McLaren KM 2002 Cytokeratin 19 and galectin-3 immunohisto chemistry in the differential diagnosis of solitary thyroidnodules. Histopathology41: 236–243[CrossRef][Medline]
[16] Valentina Guarino, Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0271
[17] Sung-Woo Kim, Sung-Chul Ho, Seong-June Hong, Kyung Min Kim, Edward C. So, Marcelo Christoffolete, and John W. Harney A Novel Mechanism of Thyroid Hormone-dependent Negative Regulation by Thyroid Hormone Receptor, Nuclear Receptor Corepressor (NCoR), and GAGA-binding Factor on the Rat CD44 PromoterJ. Biol. Chem., Apr 2005; 280: 14545 - 14555.
[18]陈宁,梁青春,甲状腺乳头状癌淋巴管密度与CD44v6表达及其意义,使用预防医学2007年6月第14卷第3期, 188
[19] Honjoy Y, InoharaH, AkahaniS,etal. Expression of cytoplasmic galectin-3 as aprognostic marker in tongue carcinoma[J].Cli CancerRes.2000,6(12):4635-4640
[20] SaggioratoE, CappiasS, DeGiuliP, etail. Galectin-3as apresurgical immuno cytodiagnostic marker of minimally invasive follicula thyroidcarcinoma[J].Jclin Endocrinol Metab.2001,86(11)5152-5158
[21] MauroPapotti ,MarcoVolante, EnricoSaggiorato, DesireeDeandreis, Roleof galectin-3 immuno detection in the cytological diagnosis of thyroid cystic papillary carcinoma, EuropeanJournalofEndocrinology(2002) 147
[22] EnricosAggiorato,SusannaCappia,PaolodeGiuli,etall galectin-3 asa Presurgical Immunocytodiagnostic Marker of Minimally Invasive Follicular Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism 86(11)5152
[23] Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. 2002 Arch Pathol Lab Med 126:710–713[Medline]
[24] Beesley MF, McLaren KM 2002 Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroidnodules. Histopathology41: 236–243[CrossRef][Medline]
[25]陈宁,梁青春,甲状腺乳头状癌淋巴管密度与CD44v6表达及其意义,使用预防医学2007年6月第14卷第3期, 188
[26] Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription- polymerase chain reaction. 2002JClinEndocrino lMetab87: 4792–4796 [Abstract/Free Full Text]
[27] Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. 2002J Clin Endocrinol Metab 87:4806–4810[Abstract/Free Full Text]
[28] Lucianemartins,Silviae.Matsuo,Katian.Ebina,Marcoaureeliov.Kulcsar,Galectin-3MessengerRibonucleicAcidandProteinAreExpressedinBenignThyroidTumorsTheJournalofClinicalEndocrinology&Metabolism87(10):4806¨C481
[29] Victorj.Bernet,Jeffreyanderyanderson,Galectin-3MessengerRibonucleicAcidOverexpressioninPapillaryThyroidCancerbyQuantitativeReverseTranscription-PolymeraseChainReactionTheJournalofClinicalEndocrinology&Metabolism87(10):4792¨C479Copyright?2002byTheEndocrineSociety doi:10.1210/jc.2002-020390
[30]王旭东,邱志强,孙保存, CD44v6基因在甲状腺乳头状癌中的表达及其临床意义,天津医科大学学报2006年第6卷第2期, 425—427
[31] EnricoSaggiorato,SausannaCappia,PaoloDeGiuli,AlessandroMussa,Galectin-3asaPresurgicalaiammunocytodiagnosticMarkerofMinimallyInvasiveFollicularThroidCarcinoma,TheJournalofClinicalEndocrinology Metabolism Vol.86,No.11 5152-5158
[32] Jorg Bojunga,Stefan Zeuzem,Molecular detection of thyroid cancer,Clinical Endocrinology,2004;61:523-530
[33]吴文君,许岗,朱圣炜,刘晓, Galectin-3对甲状腺乳头状癌早期病变的诊断意义,肿瘤防治研究2007年第34卷第7期, 815
[34] CharibH.Fine-neadleaspirationnbiopsy of thyroidnnodules;advantages,limitaticns,and effect.Mayo Clin Proc,1994,69;44-49.
[35] Takano T,Sumizaki H,Amino N.Detection of CD44variants in fine needle aspiration biopsies thytoid tumor by RT-PCR.J Exp Ciin Cancer Res;1997,16:267-271.
[36] Segev DL,Clark,Zeiger MA,et al.Beyond the suspicious thyroid fine needle aspirate.Acta Cytol,2003,47:709-722
[37] Takano T,Sumizaki H,Nakano K,et al.Increased ex pression of CD44variant in differentiated thyroid cancer J.J pn J Cancer Res,1996,87:1245-1250
[38] Hedin ger C,Williams ed,Sobin L H,et al.The WHO histological classfication of thyroid tumors:a commentary on the second editionJ.Cancer,1989,63(5):908-911
[39] Kitadai Y,Amioka T,Harumak.et al.Clinico pathological significance of vascular endothelial growth factor(VEGF)-c in human esophageal squamous cell carcinomasJ.Int J Cancer,2001,93(5):662-666
[40]桌明英,杨军军,头颈部磷癌CD44V6、P53及PCNA蛋白的表达及意义[J].耳鼻咽喉头颈外科杂志;2002;2(9)98-101
[41]李树玲,甲状腺乳头状癌551例外科主了远期疗效观察[J].中国肿瘤临床,1992:19:5-10
[42] Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol. 1999 Nov;17(11):3494-502.
[43] Coli A, Bigotti G, Zucchetti F, Negro F, Massi G. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002 Jan;40(1):80-7. Juan Rosai,Ackerman’s surgical pathology ,第九章, 512-513.
[44] Matsubayashi S, Tamai H, Morita T et al. Malignant lymphoma of the thyroid and Epstein-Barr virus. Endocrinol Jpn. 1989 Jun;36(3):343-8.
[45] Suzuki T, Takano Y, Yamashita K, Sato K, Kakita A, Okudaira M. A possible role for Epstein-Barr virus in tumorigenesis after immunosuppression in cases of renal transplantation. J Cancer Res Clin Oncol. 1993;119(10):627-9.
[46] Tomita Y, Ohsawa M, Kanno H, Matsuzuka F, Kuma K, Aozasa K. Sporadic activation of Epstein-Barr virus in thyroid lymphoma. Leuk Lymphoma. 1995 Sep;19(1-2):129-34.
[47] Takahashi K, Kashima K, Daa T, Yokoyama S, Nakayama I, Noguchi S. Contribution of Epstein-Barr virus to development of malignant lymphoma of the thyroid. Pathol Int. 1995 May;45(5):366-74.
[48] Lee RS, Schlumberger M, Caillou B, Pages F, Fridman WH, Tartour E. Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours. Eur J Cancer. 1996 Jun;32A(7):1233-9.
[49] LudvíkováM, Ryska A, KorabecnáM, RydlováM, Michal M. Oncocytic papillary carcinoma with lymphoid stroma (Warthin-like tumour) of the thyroid: a distinct entity with favourable prognosis. Histopathology. 2001 Jul;39(1): 17-24.
[50] Shimakage M, Kawahara K, Sasagawa T, Inoue H, Yutsudo M, Yoshida A, Yanoma S. Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression. Hum Pathol. 2003 Nov;34(11):1170-7.
[51] Ozyar E, Ayhan A, Korcum AF, Atahan IL. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Cancer Invest. 2004;22(4):483-91.
[52] Knight JS, Sharma N, Robertson ES. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol. 2005 Mar;25(5): 1749-63.
[53] Opitz OG, Quante M, von Werder A, Heeg S, Blum HE. A mouse model of oral-esophageal carcinogenesis. Onkologie. 2005 Jan;28(1):44-8.
[1]尼加提.热合木,居来提.吐尔荪,阿布都卡的.依马木,滤泡上皮起源甲状腺腺癌特异性生物标记物研究进展,新疆医科大学学报2007Apr., 30(4), 420-423
[2]田丰秋,吕丽,冯晓海,王乃玉,张文波,王莉芬,甲状腺乳头状癌的诊断及转移相关的免疫组化研究,中华肿瘤防治杂志2007年7月第14卷第13期, 789·
[3] BrianHung-HinLang,Chung-YauLo,Wai-FanChan,King-YinLam2andKoon-YatWanStagingsystemsforfollicularthyroidcarcinoma:applicationto171consecutivepatientstreatedinatertiaryreferralcentreEndocrine-RelatedCancer (2007) 14 29(R)C4,31-32
[4] DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006 Dec 15;94(8):662-9
[5] Valentina Guarino, Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0271
[6] Sung-Woo Kim, Sung-Chul Ho, Seong-June Hong, Kyung Min Kim, Edward C. So, Marcelo Christoffolete, and John W. Harney A Novel Mechanism of Thyroid Hormone-dependent Negative Regulation by Thyroid Hormone Receptor, Nuclear Receptor Corepressor (NCoR), and GAGA-binding Factor on the Rat CD44 PromoterJ. Biol. Chem., Apr 2005; 280: 14545 - 14555.
[7] Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Mod Pathol. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. 2006 Dec; 19(12):1631-7. Epub 2006 Sep 22
[8]王丽华,赵咏桔, Galectin-3、CD44v6在甲状腺结节型中的的表达及其意义,中华肿瘤杂志2005年第27卷第9期, 547
[9]徐莹(综述),甲状腺肿瘤Galectin-3表达及其意义, Fudan Univ J med Sci 2002 May,29(3),230-232
[10]彭年春,郭晓蕙,袁振芳,高燕明, CD26及半乳糖凝集素3免疫组织化学染色在甲状腺癌诊断中的应用,中华内分泌代谢杂志2006年4月第22卷第2期Chin J EndocrinolMetab, April2006, Vol22,No., 178
[11]倪灿荣,马大烈,戴益民,免疫组织化学实验技术及应用,一北京化学工业出版社, 2006年5月, 286
[12]肖红,段绍斌,张建勇,范健,甲状腺癌组织中galectin23、CK19的表达及应用价值,甲状腺癌组织中galectin23、CK19的表达及应用价值, 006 Nov. ,29, 1059
[13]王化修,伍石华,蒙松年,肖小芹,杨华,张灿云,存活素和CD44V6在甲状腺癌组织中的表达及意义,实用癌症杂志2006年11月第21卷第6期, 588
[2]田丰秋,吕丽,冯晓海,王乃玉,张文波,王莉芬,甲状腺乳头状癌的诊断及转移相关的免疫组化研究,中华肿瘤防治杂志2007年7月第14卷第13期, 789·
[3]桌明英,扬军,甲状腺乳头状癌中CD44v6和P53的表达及其意义,实用肿瘤学杂志2007年第21卷第3期总第89期, 253
[4]肖红,段绍斌,张建勇,范健,甲状腺组织中galectin-3、CK19的表达及应用价值,新疆医科大学学报, 2006 Nov.,29(11),9501
[5]王化修,伍石华,蒙松年,肖小芹,扬华,存活素和CD44v6在甲状腺癌组织中的表达及意义,使用癌症杂志2006年11月第21卷第6期, 885
[6]徐莹(综述),甲状腺肿瘤Galectin-3表达及其意义, Fudan Univ J med Sci 2002 May,29(3),230-232
[7]王丽华,赵咏桔, Galectin-3、CD44v6在甲状腺结节型中的的表达及其意义,中华肿瘤杂志2005年第27卷第9期, 547
[8]徐莹(综述),甲状腺肿瘤Galectin-3表达及其意义, Fudan Univ J med Sci 2002 May,29(3),230-232
[9] Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Mod Pathol. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. 2006 Dec;19(12):1631-7. Epub 2006 Sep 22
[10]王丽华,赵咏桔, Galectin-3、CD44v6在甲状腺结节型中的的表达及其意义,中华肿瘤杂志2005年第27卷第9期, 547
[11]陈宁,梁青春,甲状腺乳头状癌淋巴管密度与CD44v6表达及其意义,使用预防医学2007年6月第14卷第3期, 188
[12] BrianHung-HinLang, Chung-YauLo, Wai-FanChan, King-YinLam 2andKoon- YatWanStaging systems for follicularthyroidcarcinoma: applicationto171 consecutivepatientstreatedinatertiaryreferralcentreEndocrine-RelatedCancer (2007) 14 29(R)C4,31-32
[13] DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006 Dec 15;94(8):662-9
[14]王佾, Galectin23在甲状腺良恶性病变中的表达,中国普通外科杂志Vol.15No.1,第16卷第1期2007年1月,51-54
[15] Beesley MF, McLaren KM 2002 Cytokeratin 19 and galectin-3 immunohisto chemistry in the differential diagnosis of solitary thyroidnodules. Histopathology41: 236–243[CrossRef][Medline]
[16] Valentina Guarino, Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0271
[17] Sung-Woo Kim, Sung-Chul Ho, Seong-June Hong, Kyung Min Kim, Edward C. So, Marcelo Christoffolete, and John W. Harney A Novel Mechanism of Thyroid Hormone-dependent Negative Regulation by Thyroid Hormone Receptor, Nuclear Receptor Corepressor (NCoR), and GAGA-binding Factor on the Rat CD44 PromoterJ. Biol. Chem., Apr 2005; 280: 14545 - 14555.
[18]陈宁,梁青春,甲状腺乳头状癌淋巴管密度与CD44v6表达及其意义,使用预防医学2007年6月第14卷第3期, 188
[19] Honjoy Y, InoharaH, AkahaniS,etal. Expression of cytoplasmic galectin-3 as aprognostic marker in tongue carcinoma[J].Cli CancerRes.2000,6(12):4635-4640
[20] SaggioratoE, CappiasS, DeGiuliP, etail. Galectin-3as apresurgical immuno cytodiagnostic marker of minimally invasive follicula thyroidcarcinoma[J].Jclin Endocrinol Metab.2001,86(11)5152-5158
[21] MauroPapotti ,MarcoVolante, EnricoSaggiorato, DesireeDeandreis, Roleof galectin-3 immuno detection in the cytological diagnosis of thyroid cystic papillary carcinoma, EuropeanJournalofEndocrinology(2002) 147
[22] EnricosAggiorato,SusannaCappia,PaolodeGiuli,etall galectin-3 asa Presurgical Immunocytodiagnostic Marker of Minimally Invasive Follicular Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism 86(11)5152
[23] Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. 2002 Arch Pathol Lab Med 126:710–713[Medline]
[24] Beesley MF, McLaren KM 2002 Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroidnodules. Histopathology41: 236–243[CrossRef][Medline]
[25]陈宁,梁青春,甲状腺乳头状癌淋巴管密度与CD44v6表达及其意义,使用预防医学2007年6月第14卷第3期, 188
[26] Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription- polymerase chain reaction. 2002JClinEndocrino lMetab87: 4792–4796 [Abstract/Free Full Text]
[27] Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. 2002J Clin Endocrinol Metab 87:4806–4810[Abstract/Free Full Text]
[28] Lucianemartins,Silviae.Matsuo,Katian.Ebina,Marcoaureeliov.Kulcsar,Galectin-3MessengerRibonucleicAcidandProteinAreExpressedinBenignThyroidTumorsTheJournalofClinicalEndocrinology&Metabolism87(10):4806¨C481
[29] Victorj.Bernet,Jeffreyanderyanderson,Galectin-3MessengerRibonucleicAcidOverexpressioninPapillaryThyroidCancerbyQuantitativeReverseTranscription-PolymeraseChainReactionTheJournalofClinicalEndocrinology&Metabolism87(10):4792¨C479Copyright?2002byTheEndocrineSociety doi:10.1210/jc.2002-020390
[30]王旭东,邱志强,孙保存, CD44v6基因在甲状腺乳头状癌中的表达及其临床意义,天津医科大学学报2006年第6卷第2期, 425—427
[31] EnricoSaggiorato,SausannaCappia,PaoloDeGiuli,AlessandroMussa,Galectin-3asaPresurgicalaiammunocytodiagnosticMarkerofMinimallyInvasiveFollicularThroidCarcinoma,TheJournalofClinicalEndocrinology Metabolism Vol.86,No.11 5152-5158
[32] Jorg Bojunga,Stefan Zeuzem,Molecular detection of thyroid cancer,Clinical Endocrinology,2004;61:523-530
[33]吴文君,许岗,朱圣炜,刘晓, Galectin-3对甲状腺乳头状癌早期病变的诊断意义,肿瘤防治研究2007年第34卷第7期, 815
[34] CharibH.Fine-neadleaspirationnbiopsy of thyroidnnodules;advantages,limitaticns,and effect.Mayo Clin Proc,1994,69;44-49.
[35] Takano T,Sumizaki H,Amino N.Detection of CD44variants in fine needle aspiration biopsies thytoid tumor by RT-PCR.J Exp Ciin Cancer Res;1997,16:267-271.
[36] Segev DL,Clark,Zeiger MA,et al.Beyond the suspicious thyroid fine needle aspirate.Acta Cytol,2003,47:709-722
[37] Takano T,Sumizaki H,Nakano K,et al.Increased ex pression of CD44variant in differentiated thyroid cancer J.J pn J Cancer Res,1996,87:1245-1250
[38] Hedin ger C,Williams ed,Sobin L H,et al.The WHO histological classfication of thyroid tumors:a commentary on the second editionJ.Cancer,1989,63(5):908-911
[39] Kitadai Y,Amioka T,Harumak.et al.Clinico pathological significance of vascular endothelial growth factor(VEGF)-c in human esophageal squamous cell carcinomasJ.Int J Cancer,2001,93(5):662-666
[40]桌明英,杨军军,头颈部磷癌CD44V6、P53及PCNA蛋白的表达及意义[J].耳鼻咽喉头颈外科杂志;2002;2(9)98-101
[41]李树玲,甲状腺乳头状癌551例外科主了远期疗效观察[J].中国肿瘤临床,1992:19:5-10
[42] Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol. 1999 Nov;17(11):3494-502.
[43] Coli A, Bigotti G, Zucchetti F, Negro F, Massi G. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002 Jan;40(1):80-7. Juan Rosai,Ackerman’s surgical pathology ,第九章, 512-513.
[44] Matsubayashi S, Tamai H, Morita T et al. Malignant lymphoma of the thyroid and Epstein-Barr virus. Endocrinol Jpn. 1989 Jun;36(3):343-8.
[45] Suzuki T, Takano Y, Yamashita K, Sato K, Kakita A, Okudaira M. A possible role for Epstein-Barr virus in tumorigenesis after immunosuppression in cases of renal transplantation. J Cancer Res Clin Oncol. 1993;119(10):627-9.
[46] Tomita Y, Ohsawa M, Kanno H, Matsuzuka F, Kuma K, Aozasa K. Sporadic activation of Epstein-Barr virus in thyroid lymphoma. Leuk Lymphoma. 1995 Sep;19(1-2):129-34.
[47] Takahashi K, Kashima K, Daa T, Yokoyama S, Nakayama I, Noguchi S. Contribution of Epstein-Barr virus to development of malignant lymphoma of the thyroid. Pathol Int. 1995 May;45(5):366-74.
[48] Lee RS, Schlumberger M, Caillou B, Pages F, Fridman WH, Tartour E. Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours. Eur J Cancer. 1996 Jun;32A(7):1233-9.
[49] LudvíkováM, Ryska A, KorabecnáM, RydlováM, Michal M. Oncocytic papillary carcinoma with lymphoid stroma (Warthin-like tumour) of the thyroid: a distinct entity with favourable prognosis. Histopathology. 2001 Jul;39(1): 17-24.
[50] Shimakage M, Kawahara K, Sasagawa T, Inoue H, Yutsudo M, Yoshida A, Yanoma S. Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression. Hum Pathol. 2003 Nov;34(11):1170-7.
[51] Ozyar E, Ayhan A, Korcum AF, Atahan IL. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Cancer Invest. 2004;22(4):483-91.
[52] Knight JS, Sharma N, Robertson ES. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol. 2005 Mar;25(5): 1749-63.
[53] Opitz OG, Quante M, von Werder A, Heeg S, Blum HE. A mouse model of oral-esophageal carcinogenesis. Onkologie. 2005 Jan;28(1):44-8.
[1]尼加提.热合木,居来提.吐尔荪,阿布都卡的.依马木,滤泡上皮起源甲状腺腺癌特异性生物标记物研究进展,新疆医科大学学报2007Apr., 30(4), 420-423
[2]田丰秋,吕丽,冯晓海,王乃玉,张文波,王莉芬,甲状腺乳头状癌的诊断及转移相关的免疫组化研究,中华肿瘤防治杂志2007年7月第14卷第13期, 789·
[3] BrianHung-HinLang,Chung-YauLo,Wai-FanChan,King-YinLam2andKoon-YatWanStagingsystemsforfollicularthyroidcarcinoma:applicationto171consecutivepatientstreatedinatertiaryreferralcentreEndocrine-RelatedCancer (2007) 14 29(R)C4,31-32
[4] DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006 Dec 15;94(8):662-9
[5] Valentina Guarino, Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0271
[6] Sung-Woo Kim, Sung-Chul Ho, Seong-June Hong, Kyung Min Kim, Edward C. So, Marcelo Christoffolete, and John W. Harney A Novel Mechanism of Thyroid Hormone-dependent Negative Regulation by Thyroid Hormone Receptor, Nuclear Receptor Corepressor (NCoR), and GAGA-binding Factor on the Rat CD44 PromoterJ. Biol. Chem., Apr 2005; 280: 14545 - 14555.
[7] Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Mod Pathol. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. 2006 Dec; 19(12):1631-7. Epub 2006 Sep 22
[8]王丽华,赵咏桔, Galectin-3、CD44v6在甲状腺结节型中的的表达及其意义,中华肿瘤杂志2005年第27卷第9期, 547
[9]徐莹(综述),甲状腺肿瘤Galectin-3表达及其意义, Fudan Univ J med Sci 2002 May,29(3),230-232
[10]彭年春,郭晓蕙,袁振芳,高燕明, CD26及半乳糖凝集素3免疫组织化学染色在甲状腺癌诊断中的应用,中华内分泌代谢杂志2006年4月第22卷第2期Chin J EndocrinolMetab, April2006, Vol22,No., 178
[11]倪灿荣,马大烈,戴益民,免疫组织化学实验技术及应用,一北京化学工业出版社, 2006年5月, 286
[12]肖红,段绍斌,张建勇,范健,甲状腺癌组织中galectin23、CK19的表达及应用价值,甲状腺癌组织中galectin23、CK19的表达及应用价值, 006 Nov. ,29, 1059
[13]王化修,伍石华,蒙松年,肖小芹,杨华,张灿云,存活素和CD44V6在甲状腺癌组织中的表达及意义,实用癌症杂志2006年11月第21卷第6期, 588